Jun 15, 2021 / 12:45AM GMT
Unidentified Participant
Good morning, everyone, welcome to the MSC Access Micro Cap and Small Caps Conference. Today we're lucky enough to have Jon Pilcher who is the CEO of Neuren to present. Neuren is $150 million market cap company, and it's one of the great Australian [feel good] microcap stories on the [A6].
We certainly see Neuren as calendar year '21, calendar year '22, transformational years for the company. They're in a net cash position of about $22 million on the balance sheet. And it's a great opportunity to catch up with Neuren and to see what Jon thinks are the upcoming key moments for the company.
John's going to give a 20-minute presentation. And then after that, we'll have a short 5- to 10-minute Q&A session afterwards. (Conference Instructions) Welcome, John, and thanks for taking the time to present. I'll hand over to you.
Jon Pilcher - Neuren Pharmaceuticals Ltd - CEO & Director
Thank you, Jamie, and good morning, everyone. Thanks very much for your time this morning. So Neuren's developing two drugs to treat six different
Neuren Pharmaceuticals Ltd at MST Access Australian Micro & Small Caps Conference (Virtual) Transcript
Jun 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers